Schneider E, Fischer P A, Jacobi P, Becker H, Beyer M
J Neurol. 1979;222(1):37-43. doi: 10.1007/BF00313265.
In 92 parkinsonian patients (42 men, 50 women) aged from 37-79 years (mean 62.8) the impact of cerebral atrophy as assessed by computed tomography on the course of the clinical symptomatology under levodopa during a period of 1 to 5 years was investigated. It could be shown that patients suffering from medium to severe degrees of atrophy-independent of its special location--have a less favorable response than those with normal CT findings. The data do not allow a definite decision whether cortical artrophy or ventricular enlargement are of major importance. At any rate, the width of the third ventricle seems to have no influence on the course of the clinical symptoms. After 3 years of levodopa treatment a dissociation between cerebral atrophy and therapeutic effectiveness can be observed.
在92例年龄在37至79岁（平均62.8岁）的帕金森病患者（42名男性，50名女性）中，研究了通过计算机断层扫描评估的脑萎缩对左旋多巴治疗期间1至5年临床症状进程的影响。结果表明，患有中度至重度萎缩（无论其具体位置如何）的患者比CT检查结果正常的患者反应较差。这些数据无法确定皮质萎缩或脑室扩大哪个更为重要。无论如何，第三脑室的宽度似乎对临床症状的进程没有影响。左旋多巴治疗3年后，可以观察到脑萎缩与治疗效果之间的分离。
